Posted on 1 November 2016
Ensuring global access to proven interventions – including vaccines, drugs, and diagnostics, as well as prioritising the development of new health technologies – requires an assessment of whether the improvement in health outcomes they offer exceeds the improvement in health that would have been possible if the resources required had, instead, been made available for other health care activities. Therefore, some assessment of these health opportunity costs is required if the best use is to be made of the resources available for health care, existing technologies and the development of new ones.
More details here Informing decisions in Global Health: (PDF , 310kb)
Contact: Karl Claxton
Other Policy & Research Briefing papers can be found here